Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-12-04T15:45:24.133Z Has data issue: false hasContentIssue false

Clinical Response Predictors in a Double-Blind, Placebo-Controlled Trial of Fluoxetine for Geriatric Major Depression

Published online by Cambridge University Press:  07 January 2005

Gary W. Small
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (UCLA) School of Medicine, Los Angeles, California, U.S.A. Veterans Affairs Medical Center, West Los Angeles, California, U.S.A.
Susan H. Hamilton
Affiliation:
Lilly Research Laboratories, Indianapolis, Indiana, U.S.A.
Alexander Bystritsky
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (UCLA) School of Medicine, Los Angeles, California, U.S.A.
Barnett S. Meyers
Affiliation:
Department of Psychiatry, Cornell Medical Center Westchester Division, White Plains, New York, U.S.A.
Charles B. Nemeroff
Affiliation:
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia, U.S.A.

Abstract

Background: We attempted to determine baseline characteristics predicting response in a 6-week, double-blind, geriatric depression trial, which showed a significantly higher remission rate for fluoxetine (20 mg daily) than for placebo (31.6% vs. 18.6%, p < .001). Methods: Outpatients (N = 671) were 60 years or older (mean ± SD = 67.7 ± 5.7), met Diagnostic and Statistical Manual of Mental Disorders (3rd ed., rev., American Psychiatric Association, 1987) criteria for unipolar major depression, had baseline scores on the 17-item Hamilton Depression Rating Scale (HAMD17) of 16 or more, and were randomized after a 1-week placebo lead-in. Potential baseline predictors of percentage change in last-visit-carried-forward HAMD21 total scores were entered into a stepwise regression model. The sample was randomly divided into two groups (development and validation data sets) so that potential predictors could be confirmed in a second analysis. Results: Of the 266 variables considered for their prognostic ability, 13 were found to be significant predictors using the development data set, including (a) presence of somatic complaints, absence of agitation, and presence of previous accidental injury for fluoxetine response: and (b) reported feelings of emptiness, absence of somatic complaints, and absence of early insomnia for placebo response. The second analysis using the validation data set failed to confirm statistical significance of predictors identified in the development data set. Conclusions: Although potentially useful baseline characteristics were initially identified as response predictors, conservative statistical methods failed to confirm any significant predictors of differential responses between fluoxetine and placebo in this double-blind, placebo-controlled trial.

Type
Introduction
Copyright
© 1995 Springer Publishing Company

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)